Annexon Biosciences is a clinical-stage biopharmaceutical company that develops complementary medicines for patients with complement-mediated autoimmune, neurodegenerative, and ophthalmic disorders of the body, brain, and eye. It offers ANX005, an investigational, full-length monoclonal antibody formulated for intravenous administration for the treatment of patients with GBS; ANX007, an antigen-binding fragment formulated for intravitreal administration for the treatment of patients with geographic atrophy; ANX1502, an oral small molecule inhibitor; etc.